214 results about "AIDS diagnosis" patented technology

The invention is applicable to the technical field of biological detection, provides a fluorescence immunochromatography detection method based on monatomic nano-enzyme enhancement, and particularly relates to two application forms: in the first form, a detection signal enhanced fluorescence immunochromatography detection card and a sample diluent containing a monatomic nano-enzyme are involved; in the second form, the invention relates to a fluorescence immunochromatography detection card with enhanced detection signals, and a sample pad of the detection card is obtained by soaking a sample pad treatment solution containing a monatomic nano-enzyme solution. The two application forms both relate to a monatomic nano-enzyme solution, and the solution is composed of monatomic nano-enzyme, bio-enzyme composite microspheres, a protective agent, a surfactant, a thickening agent and a preservative. The monatomic nano enzyme is composed of an atomic-scale dispersed metal active center and a carrier material. When the method is used for detecting myocardial and inflammatory markers, the limit of quantitation can reach the pg / mL level, the detection linear range can span three orders of magnitude, and the clinical examination use requirements can be met. The kit can be applied to rapid quantitative detection of myocardial and inflammatory markers, has the advantages of high sensitivity, rapidness, convenience and high efficiency, and provides an auxiliary diagnosis basis for early screening of myocardial infarction, heart failure and infection related diseases.

The invention belongs to the technical field of biological medicine, and particularly relates to a kit for breast cancer diagnosis and application thereof. The kit comprises an elisa plate coated with a captured antibody and an HRP labeled antibody working solution, the capture antibody is a monoclonal antibody T2X-1 of an anti-PSTPIP1 protein; the HRP labeled antibody is a monoclonal antibody Z4Y-2 of an anti-PSTPIP1 protein, and the HRP labeled antibody is a monoclonal antibody Z4Y-2 of an The heavy chain amino acid sequence of the monoclonal antibody T2X-1 is as shown in SEQ ID NO.1, and the light chain amino acid sequence of the monoclonal antibody T2X-1 is as shown in SEQ ID NO.2; the heavy chain amino acid sequence of the monoclonal antibody Z4Y-2 is as shown in SEQ ID NO.3, and the light chain amino acid sequence of the monoclonal antibody Z4Y-2 is as shown in SEQ ID NO.4. The kit for breast cancer diagnosis provided by the invention can be used as an auxiliary diagnosis means for breast cancer with high expression of PSTPIP1 protein, and has high diagnostic value.

The invention discloses a mental disease medical auxiliary diagnosis method based on a bimodal knowledge graph and a related device, and relates to the technical field of mental disease diagnos.The method comprises the steps that a static medical diagnosis knowledge graph is constructed; generating a scenarized problem library based on the static medical diagnosis knowledge graph; dynamically updating a personal dynamic knowledge graph based on interaction between the scenarized question library and a user; and finally, optimizing the static medical diagnosis knowledge graph based on the personal dynamic knowledge graph. According to the invention, through cooperation of the static and dynamic knowledge maps, objectivity, dynamics and accuracy of mental disease diagnosis are improved, and closed-loop management of medical auxiliary diagnosis is realized.

The invention belongs to the field of biological medicine, and discloses a blood marker for identifying epilepsy convulsion and application thereof. The inventor finds that the LRG1 is obviously increased during epileptic convulsion, which indicates that the increase of the blood LRG1 is a blood marker during the acute attack stage of epileptic convulsion. The invention proposes and verifies that the LRG1 is the peripheral blood marker in the acute attack stage of epilepsy convulsion for the first time, and can be used as a clinical auxiliary diagnosis and treatment target.

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.

The invention relates to the technical field of tumor markers, in particular to a pancreatic cancer early screening marker combination based on blood protein and application of the pancreatic cancer early screening marker combination. Through proteomics analysis and bioinformatics screening, 12 kinds of proteins such as NME3, HPGDS, CEACAM5, TNFSF12, SCG3, VTCN1, GFRA1, KRT19, TMPRSS12, NELL2, KAZALD and MMP12 are determined to serve as the potential early screening markers of the pancreatic cancer. Researches show that the combination of the proteins can effectively distinguish pancreatic cancer patients from non-pancreatic cancer patients, and has good sensitivity and specificity. A screening model constructed based on the protein combination can be applied to auxiliary diagnosis, risk assessment and population screening of pancreatic cancer, and has important clinical transformation value.

The invention discloses a biomarker for diagnosing systemic lupus erythematosus and lupus nephritis and application of the biomarker, and relates to the technical field of biological medicines. The biomarker is an ISG15hiCD16 < + > mononuclear cell. According to the application disclosed by the invention, the ISG15hiCD16 + mononuclear cell subpopulation is found to be obviously increased in an SLE (systemic lupus erythematosus) patient. The invention also finds that the expression level of the ISG15hiCD16 + mononuclear cell subpopulation is positively correlated with the disease activity of the SLE patient, and the expression level of the ISG15hiCD16 + mononuclear cell subpopulation of the SLE patient with the kidney enduring expression is obviously higher than that of the SLE patient without the kidney enduring expression. The working characteristic curve analysis of a subject shows that the ISG15hiCD16 + mononuclear cell subset has better sensitivity and specificity for diagnosing the SLE and the LN, and has important significance for clinical auxiliary diagnosis of the SLE and the LN and illness state evaluation.

The invention provides a method and a system for predicting early gastric cancer prognosis by a circulating marker, and relates to the technical field of auxiliary diagnosis. The method comprises the following steps: performing multi-omics detection on a blood sample based on a preset sampling time sequence to obtain a multi-dimensional time sequence characteristic data set containing three groups of heterogeneous data of circulating tumor DNA, exosomes and protein markers; calculating a change slope and a fluctuation variance of the heterogeneous data in adjacent time sequence intervals, constructing a dynamic variation feature matrix in combination with a standard attenuation weighting factor, and deeply mining spatial cross-correlation and sequence dependence features of the matrix to generate a multi-modal fusion feature fingerprint; and performing regression operation on the feature fingerprints by using an integrated learning stack model to obtain a dynamic prognosis risk score, and further retrieving a risk hierarchical mapping table to generate a prognosis evaluation result containing a survival curve. According to the method, multi-modal heterogeneous data can be effectively fused, the biological dynamic characteristics in the tumor postoperative recovery phase are captured, and the accuracy and timeliness of early gastric cancer prognosis prediction are remarkably improved.

The invention relates to the technical field of medical diagnosis, and provides a multi-modal dementia analysis auxiliary diagnosis method, system and device, a medium and equipment, and the method comprises the steps: obtaining an inquiry video of a patient, and carrying out the multi-modal feature extraction of the video, and obtaining a multi-modal feature data set; analyzing the voice feature data based on a large language model and a preset voice standard to obtain voice dimension information; analyzing the text feature data based on a large language model and a preset text standard to obtain text dimension information; analyzing the visual feature data based on a large language model and a preset visual standard to obtain visual dimension information; performing time alignment processing and feature fusion processing on the modal feature data to obtain a comprehensive multi-modal feature vector; and carrying out dementia symptom diagnosis analysis based on the large language model and a pre-constructed clinical dementia rating scale, and determining a diagnosis result based on an analysis result and the modal dimension information. The accuracy and efficiency of dementia diagnosis can be improved.

The invention discloses a juvenile depressive disorder diagnosis marker, a depressive disorder diagnosis model and application thereof, and relates to the technical field of mental disorder diagnosis. Adiponectin is applied to auxiliary diagnosis or diagnosis of adolescent depressive disorder, the AUC value of a diagnosis model is larger than 0.7, and the adiponectin is high in diagnosis sensitivity and specificity and can serve as a diagnosis or auxiliary diagnosis marker of adolescent depressive disorder. Adiponectin and other indexes are combined for detection, the diagnosis performance of auxiliary diagnosis of juvenile depressive disorder can be improved, and the method has a good clinical application prospect.

The invention relates to the field of disease risk prediction models, and discloses a thyroid cancer metastasis risk prediction model and a construction method and application thereof. The construction method of the model comprises the following steps: S1, collecting and preprocessing a sample; s2, gene expression quantity detection; s3, data set division and standardization processing; s4, constructing a deep learning model; s5, performing model evaluation; and the biomarker group for detecting the gene expression quantity in the S2 is composed of RPS4Y1, PKHD1L1, CRABP1, KRT18P8, AGPAT4, CPQ, SLC26A7 and RBP4. The prediction model can be used as a clinical auxiliary diagnosis tool and is used for guiding operation range selection, postoperative follow-up visit strategy making and early intervention of high-risk patients, and the precise diagnosis and treatment level of thyroid cancer is improved.

This invention discloses an ANXA1 recombinant antigen, its preparation method, and its applications, belonging to the field of biodetection technology. The ANXA1 recombinant antigen of this invention is based on the wild-type ANXA1 protein shown in SEQ ID NO.1, obtained by deleting its first epitope-masking region, thus making the epitope more easily exposed. Verification has shown that, compared to the full-length ANXA1 antigen, the ANXA1 recombinant antigen of this invention has improved sensitivity in early lung cancer detection, and its detection performance is significantly superior to commercially available ANXA1 recombinant antigens. Therefore, the ANXA1 recombinant antigen of this invention provides a new approach for the early auxiliary diagnosis of lung cancer.

This invention discloses an anti-HIV antibody or a functional fragment thereof and its applications. The anti-HIV antibody or functional fragment disclosed in this invention includes a heavy chain complementarity-determining region and a light chain complementarity-determining region. This antibody or functional fragment has good specificity and sensitivity for HIV and can be used to detect human immunodeficiency virus (HIV) and for the diagnosis or auxiliary diagnosis of related diseases using HIV as a biomarker.

The application relates to the field of biological medicine, discloses application of a biomarker in an in-vitro auxiliary diagnosis product of sepsis complicated with ARDS, the biomarker is PDLIM1 in peripheral blood; further includes a detection kit and a use method thereof. The application first proposes that the PDLIM1 protein can be used as a biomarker to detect sepsis complicated with ARDS, compared with detection by means of a "combined judgment" method, the detection product can help medical staff to perform rapid detection, and in a ROC curve diagram, the AUC of PDLIM1 is greater than 0.8, the detection result is reliable, and the operation mode is relatively simple, so that the detection time is compressed, and the medical starting time is reduced.

The application relates to the field of disease prediction, and particularly relates to an epilepsy prediction system based on electroencephalogram-electrogastrogram signals collected synchronously, which comprises the following modules: a data acquisition module, which is used for acquiring data, wherein the data comprises electroencephalogram data and electrogastrogram data; a first analysis module, which is used for obtaining average electrode inconsistency indexes of first channels and second channels based on a first model according to time sequence data; and a prediction module, which is used for comparing the average electrode inconsistency indexes of a subject with preset evaluation thresholds, so as to predict epilepsy patients. The system provided by the application can more accurately and efficiently distinguish epilepsy patients from healthy people, and can be applied to the preliminary screening of epilepsy for a large population (for example, a community or a physical examination center) as an auxiliary diagnosis tool.

The invention discloses a human papilloma virus mRNA (messenger ribonucleic acid) detection kit for auxiliary diagnosis of cervical cancer patients. The human papilloma virus mRNA detection kit comprises a nucleic acid probe group and a series of nucleic acid probes AMP1-AMP5, wherein the nucleic acid probe group is used for being combined with a human papilloma virus mRNA target, and the nucleic acid probes AMP1-AMP5 are used for signal amplification. The human papilloma virus mRNA detection kit provided by the invention can assist pathologists in identifying and diagnosing cervical cancer patients, and provides a basis for clinicians to formulate a therapeutic schedule.

The utility model discloses a portable traditional Chinese medicine olfactory diagnosis instrument, which comprises a sample collection device, a gas enrichment device, a mass spectrometer, a data processor and a display, the mass spectrometer is sequentially connected with the data processor and the display, the gas enrichment device is test paper with an enrichment reagent encapsulating nano-metal particles, the enrichment efficiency is effectively improved, and the detection accuracy is improved. Therefore, the detection sensitivity and accuracy of the mass spectrometer are improved; the device is provided with the ion trap mass spectrometer, has the characteristics of high detection speed, high resolution and high sensitivity, and has performance advantages in qualitative and trace analysis aspects; and due to small volume and strong portability, the device can be conveniently integrated into portable or field detection equipment, can be used for auxiliary diagnosis of heart failure and asthma, and also has great clinical application value in the aspects of disease evolution and disease prognosis evaluation.

This invention belongs to the fields of pharmaceutical biotechnology and clinical medicine, specifically relating to a peripheral blood phosphatidylethanolamine biomarker for the objective diagnosis of depression, and particularly to the application of phosphatidylethanolamine (PE) (18:1 / 18:3) in the diagnosis and risk assessment of depression. This invention provides an objective diagnostic method based on peripheral blood, overcoming the inherent subjectivity of traditional psychiatric diagnoses, and can be used for the auxiliary diagnosis, early screening, and risk assessment of depression.

The invention discloses an interpretable machine learning method for predicting multi-organ injuries of diquat poisoning patients, and the method comprises the steps: constructing and verifying a prediction system of eight kinds of organ injuries through a clinical database; toxic encephalopathy, myocardial injury, acute kidney injury, circulatory failure, skeletal muscle injury, liver injury, lung injury and gastrointestinal tract injury are covered. According to the method, early-stage efficient prediction of multi-organ injury is achieved, deep insight is provided for potential biological mechanisms of organ injury, clinical formulation of individualized intervention strategies is facilitated, the prognosis management level of diquat poisoning patients is expected to be remarkably improved, and the incidence rate and case fatality rate of multi-organ failure are reduced. According to the technical scheme, high prediction precision is kept, meanwhile, balance of interpretability, stability and clinical applicability of the model is achieved, a reliable auxiliary diagnosis tool is provided for organ injury risk assessment of acute poisoning patients, and the method has important clinical application value and wide market prospects.

The application discloses a cervical cancer methylation detection kit and application thereof, the kit takes PAX5 gene, PAX1 gene, MICOS10-NBL1 gene and MICOS10 gene as detection targets; the kit mainly comprises specific primer probe dry powder combination, PCR reaction reagent dry powder, positive control product dry powder, negative control product dry powder and microdroplet generation oil. The sample is detected by bisulfite conversion, and the kit is combined with microdroplet digital PCR detection technology to realize accurate detection of the methylation level of the target gene. The detection verification result shows that the sensitivity of the kit for cervical cancer detection reaches 96.9%, the specificity reaches 95.7%, the kit has the advantages of accurate detection, simple operation and strong stability, can be widely applied to early screening, clinical auxiliary diagnosis and physical examination of healthy people of cervical cancer, and provides reliable technical support for early discovery and early treatment of cervical cancer.

The invention discloses a MAGE A1 recombinant antigen as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The amino acid sequence of the MAGE A1 recombinant antigen disclosed by the invention is as shown in SEQ ID NO. 1. Through verification, compared with a full-length MAGE A1 antigen, the MAGE A1 recombinant antigen disclosed by the invention has the advantage that the sensitivity of the MAGE A1 recombinant antigen in early lung cancer detection is improved. Therefore, the MAGE A1 recombinant antigen provides a new way for early auxiliary diagnosis of lung cancer.

The invention belongs to the technical field of biological medicine, and relates to a novel application of endogenous substances in alcohol related liver disease (ALD). The invention proposes for the first time that an endogenous substance with regular concentration change in the ALD process can be used as a biomarker for auxiliary diagnosis and / or stage evaluation of ALD, the exogenous supplement of the endogenous substance has a prevention and treatment effect on ALD, and the endogenous substance has double values of being used as an excellent biomarker and an effective therapeutic agent. The substances include but are not limited to taurochenodeoxycholic acid (TCDCA), dehydroepiandrosterone sulfate (DHEA-S) and the like. Wherein the serum concentration of TCDCA is obviously increased along with disease progression, and the concentration of DHEA-S is obviously reduced. The diagnostic value of the substance on ALD is remarkably superior to that of a traditional liver injury marker, and ethanol-induced liver cell injury and mouse liver pathological change can be remarkably improved through exogenous supplementation. The invention provides a brand new strategy for accurate diagnosis and prevention of ALD.

The application discloses a use of ubiquitination as a marker of systemic juvenile idiopathic arthritis, and relates to the technical field of biomedicine. The marker provided by the application is a gene combination of at least two genes in ubiquitination which participates in the occurrence of sJIA inflammation by mediating NLRs pathway; the ubiquitination includes HP, S100A9, S100A12, S100A8, IL6, CFH and UBE2D1; and the gene combination at least includes a combination of any one of HP and IL6 and UBE2D1. The application constructs a joint detection scheme of UBE2D1 and inflammatory factors, chemotactic factors or immune-related molecules, and can make up for the problems of insufficient stability or limited specificity of a single index to some extent, thereby improving the auxiliary diagnosis efficiency on sJIA. Meanwhile, the detection object involved in the application is clear, the detection mode is feasible, the detection can be carried out based on a blood sample, and the application has the advantages of relatively simple operation, strong clinical implementability, convenience for development into a detection kit, a detection chip or a matching detection reagent.

This application provides a monoclonal antibody combination against NFL protein and its uses. The monoclonal antibody combination includes a first antibody and a second antibody. The first antibody includes a first heavy chain variable region and a first light chain variable region, and the second antibody includes a second heavy chain variable region and a second light chain variable region. The first heavy chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:3-5, the first light chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:6-8, the second heavy chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:11-13, and the second light chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:14-16. The monoclonal antibody combination provided in this embodiment has excellent specificity and high affinity, and can be used for in vitro quantitative detection of serum NFL concentration, providing technical support for the auxiliary diagnosis of neurological diseases.

In the first aspect, at least one of phosphatidylinositol 4-kinase type 2 alpha, phosphatidylinositol 5-phosphate 4-kinase type 2 alpha and protein kinase C beta is used as a marker to prepare a detection reagent or a kit so as to realize diagnosis or auxiliary diagnosis of Parkinson's disease. The kinases detected in an erythrocyte membrane as the PD diagnosis marker have the following advantages: 1, hemoglobin interference can be effectively removed through hypotonic lysis / centrifugal separation, the detection stability is improved, and accurate discovery of the marker is facilitated; 2, the erythrocyte membrane is easy to obtain and noninvasive, so that great convenience is provided for popularization of detection; 3, the biomarker found based on the erythrocyte membrane can be popularized or combined with serum detection, and it is possible to efficiently and stably detect PD.

The application belongs to the technical field of biological medicine, and particularly discloses an application of insulin-like growth factors binding protein 6 (IGFBP6) as a biomarker in preparation of a sepsis diagnosis and treatment reagent. It is found by the application that IGFBP6 can be used as a new biological marker for assisting in diagnosis of sepsis, and can be used not only for diagnosis of diseases and reflecting severity of diseases, but also as a potential sepsis treatment target, so that a new technical means is provided for diagnosis, prognosis and treatment of sepsis diseases.

The application discloses a marker group for liver cancer screening and diagnosis and application thereof, and belongs to the field of molecular biological technology.The marker group comprises at least four polypeptides shown in sequences SEQ ID NO.1-35.The marker group constructed by the application has more excellent sensitivity and specificity when used for the auxiliary diagnosis and early screening of liver cancer, is superior to a GALAD model recommended by a current liver cancer clinical guideline and a detection kit based on seven miRNAs, and is also superior to AFP-L3% and PIVKA-II recommended by a current liver cancer early screening expert consensus, and is expected to be applied to the diagnosis and treatment of liver cancer.

The invention discloses a marker combination for diagnosing heart failure blood stasis syndrome and application thereof, the marker combination comprises a marker A and a marker B, the marker A is Cr, and the marker B is selected from at least one of PCSK9, AFM and APOC1. The marker combination provided by the invention is applied to clinical diagnosis or auxiliary diagnosis of heart failure blood stasis syndrome patients, has relatively high sensitivity and specificity, and can effectively distinguish the heart failure blood stasis syndrome patients from heart failure non-blood-stasis syndrome patients; reliable basis and practical guidance can be provided for clinical diagnosis and drug treatment of the heart failure blood stasis syndrome, and the accuracy and standardization degree of traditional Chinese medicine syndrome differentiation diagnosis can be improved.

Embodiments of the instant disclosure relate to an in vitro system for generating 3D skin equivalent, compositions, and methods for modeling and analyzing potential therapeutic treatments of Ehlers-Danlos Syndrome (EDS), including personalized therapies and regimens. In certain embodiments, the in vitro system can be utilized to facilitate diagnosis, drug discovery, investigation of disease mechanisms, and treatment of EDS and other connective tissue diseases. In certain embodiments, compositions, and methods for making and using matrix metalloproteinase 9 (MMP-9) inhibitors are disclosed to treat EDS. In some embodiments, a subject has hypermobility type EDS (hEDS).

To provide a method for acquiring data for assisting the diagnosis of psychoneurotic diseases in male infants based on an objective index, and to provide a kit for assisting the diagnosis of psychoneurotic diseases in male infants.SOLUTION: A method for acquiring data for assisting the diagnosis of psychoneurotic disorders in male infants includes a detection step of detecting dihydroxy-eicosatrienoic acid contained in a sample collected from a living body.SELECTED DRAWING: None